Abstract
Hypermethylation of CpG island promoters is associated with transcriptional inactivation of tumor suppressor genes in neoplasia. Inactivation of p16 and Pten was related to the development of pheochromocytomas. In this report, we investigated the methylation status of the p16INK4a
cell cycle inhibitor gene and other prominent tumor-related genes (PTEN, RASSF1 A, CDH1, MSH2, MLH1, VHL, and TIMP3) in sporadic and multiple endocrine neoplasia type 2 (MEN2) pheochromocytomas by methylation-specific PCR. Hypermethylation was detected in 48 % of pheochromocytomas for RASSF1 A, 24 % for p16, 36 % for MSH2, 16 % for CDH1, and 8 % for PTEN. No VHL, MLH1, and TIMP3 methylation was observed. Interestingly, the frequency of p16 inactivation in familial tumors was higher (5 out of 12, 42 %) than in sporadic tumors (1 out of 13, 8 %; p = 0.047) and RASSF1 A inactivation was more common in the hereditary tumors (58 %) compared to the sporadic tumors (38 %). Combined methylation of RASSF1 A and p16 was found only in MEN2-related pheochromocytomas. Thus, a subset of hereditary pheochromocytomas displays preferential methylation of p16 and RASSF1 A.
Key words
Pheochromocytoma - multiple endocrine neoplasia type 2 - methylation - tumor suppressor gene
References
-
1
Agathanggelou A, Bieche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, Gao B, Minna J D, Downward J, Maher E R, Latif F.
Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1 A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.
Cancer Res.
2003;
63
5344-5351
-
2
Agathanggelou A, Honorio S, Macartney D P, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw J A, Hosoe S, Lerman M I, Minna J D, Maher E R, Latif F.
Methylation associated inactivation of RASSF1 A from region 3 p21. 3 in lung, breast and ovarian tumours.
Oncogene.
2001;
20
1509-1518
-
3
Ahuja N, Li Q, Mohan A L, Baylin S B, Issa J P.
Aging and DNA methylation in colorectal mucosa and cancer.
Cancer Res.
1998;
58
5489-5494
-
4
Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann H P, Voutilainen R, Dahia P, Eng C, Maher E R, Latif F.
RASSF1 A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Oncogene.
2001 a;
20
7573-7577
-
5
Astuti D, Latif F, Dallol A, Dahia P L, Douglas F, George E, Skoldberg F, Husebye E S, Eng C, Maher E R.
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
Am J Hum Genet.
2001 b;
69
49-54
-
6
Bender B U, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, Neumann H P.
Differential genetic alterations in von Hippel-Lindau syndrome- associated and sporadic pheochromocytomas.
J Clin Endocrinol Metab.
2000;
85
4568-4574
-
7
Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, Decker H J.
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Cancer Res.
2000;
60
1942-1948
-
8
Burbee D G, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar A F, Lerman M I, Zabarovsky E, White M, Minna J D.
Epigenetic inactivation of RASSF1 A in lung and breast cancers and malignant phenotype suppression.
J Natl Cancer Inst.
2001;
93
691-699
-
9
Califano D, Rizzo C, D'Alessio A, Colucci-D'Amato G L, Cali G, Bartoli P C, Santelli G, Vecchio G, de Franciscis V.
Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells.
J Biol Chem.
2000;
275
19297-19305
-
10
Campbell S L, Khosravi-Far R, Rossman K L, Clark G J, Der C J.
Increasing complexity of Ras signaling.
Oncogene.
1998;
17
1395-1413
-
11
Clark S J, Harrison J, Paul C L, Frommer M.
High sensitivity mapping of methylated cytosines.
Nucleic Acids Res.
1994;
22
2990-2997
-
12
Clifford S C, Prowse A H, Affara N A, Buys C H, Maher E R.
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3 p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Genes Chromosomes Cancer.
1998;
22
200-209
-
13
Dammann R, Li C, Yoon J H, Chin P L, Bates S, Pfeifer G P.
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3 p21. 3.
Nat Genet.
2000;
25
315-319
-
14
Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm B O, Pfeifer G P, Hoang-Vu C.
Frequent RASSF1 A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Oncogene.
2003 a;
22
3806-3812
-
15
Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer G P.
Epigenetic inactivation of the Ras-association domain family 1 (RASSF1 A) gene and its function in human carcinogenesis.
Histol Histopathol.
2003 b;
18
665-677
-
16
Dannenberg H, Speel E J, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz P U, Bonjer H J, Dinjens W N, Mooi W J, Komminoth P, de Krijger R R.
Losses of chromosomes 1 p and 3 q are early genetic events in the development of sporadic pheochromocytomas.
Am J Pathol.
2000;
157
353-359
-
17
Dreijerink K, Braga E, Kuzmin I, Geil L, Duh F M, Angeloni D, Zbar B, Lerman M I, Stanbridge E J, Minna J D, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky E R.
The candidate tumor suppressor gene, RASSF1 A, from human chromosome 3 p21. 3 is involved in kidney tumorigenesis.
Proc Natl Acad Sci U S A.
2001;
98
7504-7509
-
18
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R F, van Amstel H K, Lips C J, Nishisho I, Takai S I, Marsh D J, Robinson B G, Frank-Raue K, Raue F, Xue F, Noll W W, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy G N, Mulligan L M.
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
JAMA.
1996;
276
1575-1579
-
19
Esteller M, Fraga M F, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin A K, Trojan J, Vaurs-Barriere C, Bignon Y J, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal M J, Rodriguez R, Capella G, Peinado M A, Borg A, Aaltonen L A, Ponder B A, Baylin S B, Herman J G.
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
Hum Mol Genet.
2001;
10
3001-3007
-
20
Gimm O, Armanios M, Dziema H, Neumann H P, Eng C.
Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.
Cancer Res.
2000;
60
6822-6825
-
21
Glasker S, Bender B U, Apel T W, van Velthoven V, Mulligan L M, Zentner J, Neumann H P.
Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
J Neurol Neurosurg Psychiatry.
2001;
70
644-648
-
22
Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka K O, Timmons C F, Tomlinson G E, Mastrangelo D, Hay R J, Minna J D, Gazdar A F.
Aberrant promoter methylation and silencing of the RASSF1 A gene in pediatric tumors and cell lines.
Oncogene.
2002;
21
4345-4349
-
23
Herman J G, Graff J R, Myohanen S, Nelkin B D, Baylin S B.
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Proc Natl Acad Sci USA.
1996;
93
9821-9826
-
24
Herman J G, Latif F, Weng Y, Lerman M I, Zbar B, Liu S, Samid D, Duan D S, Gnarra J R, Linehan W M, Baylin S B.
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Proc Natl Acad Sci USA.
1994;
91
9700-9704
-
25
Herman J G, Umar A, Polyak K, Graff J R, Ahuja N, Issa J P, Markowitz S, Willson J K, Hamilton S R, Kinzler K W, Kane M F, Kolodner R D, Vogelstein B, Kunkel T A, Baylin S B.
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.
Proc Natl Acad Sci USA.
1998;
95
6870-6875
-
26
Jones P A, Baylin S B.
The fundamental role of epigenetic events in cancer.
Nat Rev Genet.
2002;
3
415-428
-
27
Katz M E, McCormick F.
Signal transduction from multiple Ras effectors.
Curr Opin Genet Dev.
1997;
7
75-79
-
28
Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X F, Seed B, Avruch J.
Identification of a novel Ras-regulated proapoptotic pathway.
Curr Biol.
2002;
12
253-265
-
29
Koch C A, Vortmeyer A O, Huang S C, Alesci S, Zhuang Z, Pacak K.
Genetic aspects of pheochromocytoma.
Endocr Regul.
2001;
35
43-52
-
30
Kok K, Naylor S L, Buys C H.
Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes.
Adv Cancer Res.
1997;
71
27-92
-
31
Liu B, Parsons R, Papadopoulos N, Nicolaides N C, Lynch H T, Watson P, Jass J R, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton S R, Vogelstein B, Kinzler K W.
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients.
Nat Med.
1996;
2
169-174
-
32
Liu L, Tommasi S, Lee D H, Dammann R, Pfeifer G P.
Control of microtubule stability by the RASSF1 A tumor suppressor.
Oncogene.
2003;
22
8125-8136
-
33
Lo K W, Kwong J, Hui A B, Chan S Y, To K F, Chan A S, Chow L S, Teo P M, Johnson P J, Huang D P.
High frequency of promoter hypermethylation of RASSF1 A in nasopharyngeal carcinoma.
Cancer Res.
2001;
61
3877-3881
-
34
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan N V, Moch H, Richards F M, Kishida T, Yao M, Schraml P, Latif F, Maher E R.
Epigenetic inactivation of the RASSF1 A 3 p21. 3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Cancer Res.
2001;
61
7277-7281
-
35
Murata H, Khattar N H, Kang Y, Gu L, Li G M.
Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability.
Oncogene.
2002;
21
5696-5703
-
36
Neumann H P, Bausch B, McWhinney S R, Bender B U, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith W M, Munk R, Manz T, Glaesker S, Apel T W, Treier M, Reineke M, Walz M K, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C.
Germ-line mutations in nonsyndromic pheochromocytoma.
N Engl J Med.
2002;
346
1459-1466
-
37
Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe H H, Pfeifer G P, Schlegelberger B, Dammann R.
Frequent epigenetic inactivation of the RASSF1 A gene in hepatocellular carcinoma.
Oncogene.
2003;
22
1866-1871
-
38
Shivakumar L, Minna J, Sakamaki T, Pestell R, White M A.
The RASSF1 A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.
Mol Cell Biol.
2002;
22
4309-4318
-
39
Toyota M, Issa J P.
The role of DNA hypermethylation in human neoplasia.
Electrophoresis.
2000;
21
329-333
-
40
Tse J Y, Wong J H, Lo K W, Poon W S, Huang D P, Ng H K.
Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas.
Am J Clin Pathol.
1997;
107
459-466
-
41
Vargas M P, Zhuang Z, Wang C, Vortmeyer A, Linehan W M, Merino M J.
Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma.
Hum Pathol.
1997;
28
411-415
-
42
Wallace M R, Marchuk D A, Andersen L B, Letcher R, Odeh H M, Saulino A M, Fountain J W, Brereton A, Nicholson J, Mitchell A L, Brownstein B H, Collins F S.
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.
Science.
1990;
249
181-186
-
43
Wang Y C, Lu Y P, Tseng R C, Lin R K, Chang J W, Chen J T, Shih C M, Chen C Y.
Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.
J Clin Invest.
2003;
111
887-895
-
44
Woodward E R, Eng C, McMahon R, Voutilainen R, Affara N A, Ponder B A, Maher E R.
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
Hum Mol Genet.
1997;
6
1051-1056
-
45
Xiong Z, Laird P W.
COBRA: a sensitive and quantitative DNA methylation assay.
Nucleic Acids Res.
1997;
25
2532-2534
-
46
Yoon J H, Dammann R, Pfeifer G P.
Hypermethylation of the CpG island of the RASSF1 A gene in ovarian and renal cell carcinomas.
Int J Cancer.
2001;
94
212-217
-
47
You M J, Castrillon D H, Bastian B C, O'Hagan R C, Bosenberg M W, Parsons R, Chin L, DePinho R A.
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.
Proc Natl Acad Sci USA.
2002;
99
1455-1460
-
48
Zeiger M A, Zbar B, Keiser H, Linehan W M, Gnarra J R.
Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma.
Genes Chromosomes Cancer.
1995;
13
151-156
1 * contributed equally to this work
Dr. Reinhard Dammann
Institut für Humangenetik und Medizinische Biologie
Martin-Luther-Universität Halle-Wittenberg
Magdeburger Straße 2
06097 Halle/Saale
Germany
Telefon: + 493455574537
Fax: + 49 34 55 57 42 93
eMail: reinhard.dammann@medizin.uni-halle.de
